John Demaree Net Worth & Insider Trades

John Demaree - Chief Commercial Officer, Karyopharm Therapeutics Inc

As of March 1, 2021

What is John Demaree's Net Worth?

The current estimated net worth of Karyopharm Therapeutics Inc's Chief Commercial Officer, John Demaree, is estimated to be about $28.11K . John Demaree owns about 7,500 units of Karyopharm Therapeutics Inc common stock. In the last year at Karyopharm Therapeutics Inc, John Demaree has sold an estimated value of $0 worth.

What is John Demaree's Past Insider Trading?

John Demaree's largest purchase order was 7,500 units , worth over $109.01K on August 27, 2020. In total, John Demaree has made about 3 transactions over a year of their time at Karyopharm Therapeutics Inc. John Demaree usually trades in March, with the busiest year in 2020.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

John Demaree

Date Range: All Time
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...

InsideArbitrage

Our partner InsideArbitrage provides a full suite of tools and analysis that allows you to find opportunities from the hundreds of insiders transactions filed by company insiders each week. The service includes the popular Insider Weekends articles that highlight the top 5 insider purchases and sales each week as well as detailed analysis of one company each week. The service also includes several custom screens such as the Double Dipper that includes a list of companies that are buying back their shares while their insiders are independently buying stock on the open market for their own portfolios.

What is John Demaree's' Mailing Address?

  • Mailing address is 79 TW Alexander Drive 4501 Research Commons, Suite 100 Research Triangle Park NC 27709 NC

What are Karyopharm Therapeutics Inc's Past Insider Trades?

Karyopharm Therapeutics Inc's most recent insider trade came on September 12, 2023 by Garen Bohlin who bought 41,140 units worth $49.99K . In the last 10 years, insiders at Karyopharm Therapeutics Inc have sold an estimated value of $148.23M and bought an estimated value of $33.49M worth of shares. Insider trading is most common in February, with the busiest year in 2018. The most active traders at the company are Sharon Shacham, Chief Scientific Officer,  Michael Kauffman, Director,  and Andreas Hadjimichael .

Karyopharm Therapeutics Inc. Insider Trades

Date Range: All Time
Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...